Indication
Primary Immunodeficiency Diseases
9 clinical trials
9 products
Clinical trial
A Phase 3, Open-label, Non-controlled, Multi-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Efficacy of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Subjects With Primary Immunodeficiency Diseases (PID)Status: Completed, Estimated PCD: 2021-12-22
Product
Immune GlobulinProduct
Immune Globulin IntravenousClinical trial
A Phase 3, Open-label, Non-controlled, Extension Study to Evaluate the Long-term Safety of TAK-771 in Japanese Patients With Primary Immunodeficiency Disease (PID)Status: Active (not recruiting), Estimated PCD: 2025-04-30
Product
TAK-771Product
Immune Globulin SubcutaneousProduct
TAK-881Product
HYQVIAClinical trial
Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)Status: Recruiting, Estimated PCD: 2026-02-10
Clinical trial
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects With Primary Immunodeficiency DiseasesStatus: Completed, Estimated PCD: 2021-01-15
Product
KIOVIGProduct
CuvitruClinical trial
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)Status: Completed, Estimated PCD: 2021-10-21
Clinical trial
Long-term Safety and Tolerability of TAK-881 in Subjects With Primary Immunodeficiency Diseases (PIDD)Status: Not yet recruiting, Estimated PCD: 2027-05-07
Clinical trial
A Phase 3, Open-label, Non-controlled Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Efficacy of TAK-771 in Japanese Subjects With Primary Immunodeficiency Diseases (PID)Status: Completed, Estimated PCD: 2023-08-28
Clinical trial
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric Subjects With Primary Immunodeficiency DiseasesStatus: Completed, Estimated PCD: 2022-07-20
Clinical trial
Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary ImmunodeficienciesStatus: Recruiting, Estimated PCD: 2023-07-31
Product
Cutaquig